{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:05:13Z","timestamp":1779379513094,"version":"3.53.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Hypertrophic pachymeningitis (HP) is a rare disorder characterized by focal or diffuse inflammatory thickening of the dura mater. Patients may present with prolonged localized central nervous system involvement and often lack the typical manifestations of ANCA-associated vasculitis (AAV), making diagnosis and treatment challenging. We report the case of a 55-year-old woman who presented with recurrent headache, right eye pain, and visual decline. Laboratory testing showed positivity for myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA), and brain magnetic resonance imaging (MRI) demonstrated extensive dural thickening and enhancement involving the bilateral cerebral convexities, falx cerebri, and cerebellar tentorium. Based on the clinical, laboratory, and imaging findings, she was diagnosed with MPO-ANCA-associated hypertrophic pachymeningitis. During follow-up, the patient experienced multiple relapses and showed poor tolerance to several immunosuppressive agents. She was subsequently treated with low-dose rituximab (100\u202fmg) for induction and maintenance therapy. After treatment, her clinical symptoms improved, and the dural thickening and enhancement on imaging were alleviated. During follow-up, she developed proteinuria and hematuria, and renal biopsy ultimately confirmed microscopic polyangiitis (MPA). After intensified treatment, inflammatory markers and renal involvement were brought under control. This case suggests that, in patients with recurrent MPO-ANCA-associated hypertrophic pachymeningitis who are intolerant to multiple immunosuppressive agents, an individualized low-dose rituximab regimen may help achieve a period of clinical and radiological remission.<\/jats:p>","DOI":"10.3389\/fmed.2026.1843169","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:11:46Z","timestamp":1779376306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose rituximab for MPO-ANCA-associated hypertrophic pachymeningitis with delayed onset of renal involvement: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Haohu","family":"Wu","sequence":"first","affiliation":[{"name":"Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongguan","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Yao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiqi","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Province University Clinical Immunology Translational Medicine Laboratory","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"103338","DOI":"10.1016\/j.autrev.2023.103338","article-title":"Hypertrophic pachymeningitis in ANCA-associated vasculitis: clinical and immunopathological features and insights","volume":"22","author":"Shimojima","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/brain\/awt314","article-title":"Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody","volume":"137","author":"Yokoseki","year":"2014","journal-title":"Brain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"103285","DOI":"10.1016\/j.autrev.2023.103285","article-title":"Pachymeningitis associated with IgG4-related disease and ANCA positivity: case report and review of the literature","volume":"22","author":"Gautier","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1097\/rhu.0000000000001845","article-title":"Isolated myeloperoxidase-antineutrophil cytoplasmic antibody-associated hypertrophic pachymeningitis","volume":"28","author":"Maneval","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.5692\/clinicalneurol.cn-000719","article-title":"A case of MPO-ANCA positive hypertrophic pachymeningitis associated with vascular inflammation in the kidney biopsy","volume":"55","author":"Takewaki","year":"2015","journal-title":"Rinsho Shinkeigaku"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1212\/01.wnl.0000143063.12569.fc","article-title":"Hypertrophic pachymeningitis as an initial and cardinal manifestation of microscopic polyangiitis","volume":"63","author":"Furukawa","year":"2004","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12026-016-8863-1","article-title":"Idiopathic hypertrophic pachymeningitis: an autoimmune IgG4-related disease","volume":"65","author":"De Virgilio","year":"2017","journal-title":"Immunol Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2169\/naika.104.1635","article-title":"A case of microscopic polyangiitis with hypertrophic pachymeningitis and diabetes insipidus","volume":"104","author":"Takahashi","year":"2015","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2169\/internalmedicine.47.0505","article-title":"Fatal hemoperitoneum preceded by cranial hypertrophic pachymeningitis in a patient with ANCA-positive microscopic polyangitis","volume":"47","author":"Hayashi","year":"2008","journal-title":"Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5692\/clinicalneurol.cn-000859","article-title":"A case of myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated hypertrophic pachymeningitis presenting with multiple cranial nerve palsies and diabetes insipidus","volume":"56","author":"Yasuda","year":"2016","journal-title":"Rinsho Shinkeigaku"},{"key":"ref14","first-page":"151","article-title":"Hypertrophic pachymeningitis, glomerulonephritis and P-ANCA associated small vessel vasculitis","volume":"67","author":"Mazzocchi","year":"2007","journal-title":"Medicina (B Aires)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"ref16","first-page":"176","article-title":"Efficacy of rituximab for anti-neutrophil cytoplasmic antibody-associated hypertrophic pachymeningitis: a case series","volume":"38","author":"Kobayashi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3988\/jcn.2017.13.2.155","article-title":"Rituximab treatment for idiopathic hypertrophic pachymeningitis","volume":"13","author":"Jang","year":"2017","journal-title":"J Clin Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10067-009-1291-z","article-title":"Successful treatment of hypertrophic pachymeningitis in refractory Wegener\u2019s granulomatosis with rituximab","volume":"29","author":"Sharma","year":"2010","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.2147\/jir.S521138","article-title":"MPO-ANCA-associated hypertrophic pachymeningitis mimicking IgG4-related disease: a case report and literature review","volume":"18","author":"Chen","year":"2025","journal-title":"J Inflamm Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12882-023-03075-8","article-title":"Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series","volume":"24","author":"Liu","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5414\/cp203453","article-title":"Clinical efficacy of low-dose rituximab on hematological abnormalities in patients with connective tissue disease","volume":"57","author":"Wang","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","article-title":"First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of lupus (GLADEL, Grupo Latino americano de Estudio del lupus)-Pan-American league of associations of rheumatology (PANLAR)","volume":"77","author":"Pons-Estel","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1681\/asn.2014100997","article-title":"Understanding the role of rituximab in ANCA GN: regressing toward the mean","volume":"26","author":"Pendergraft","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/ijms23010387","article-title":"B lineage cells in ANCA-associated vasculitis","volume":"23","author":"Merino-Vico","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1681\/asn.2017040367","article-title":"Targeting B cells and plasma cells in glomerular diseases: translational perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10067-018-4372-z","article-title":"Incidence and risk factors of new-onset hypertrophic pachymeningitis in patients with anti-neutrophil antibody-associated vasculitis: using logistic regression and classification tree analysis","volume":"38","author":"Imafuku","year":"2019","journal-title":"Clin Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12883-024-03785-y","article-title":"Two cases of MPO-ANCA-positive hypertrophic pachymeningitis mimicking as intracranial infection","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1616837","DOI":"10.3389\/fimmu.2025.1616837","article-title":"Biomarkers in ANCA associated vasculitis: clinical utility, pitfalls and their role in the outcomes assessment","volume":"16","author":"Marvisi","year":"2025","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/rheumatology\/keae293","article-title":"Distinct features of ANCA-associated hypertrophic pachymeningitis compared with other etiologies: findings from a study of 74 patients","volume":"64","author":"Mart\u00edn-Nares","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e24388","DOI":"10.1097\/md.0000000000024388","article-title":"Hypertrophic spinal pachymeningitis caused by ANCA-associated vasculitis revealed by 18F-FDG PET\/CT: a case report","volume":"100","author":"Wu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0042-1750014","article-title":"Hypertrophic pachymeningitis presenting as \u201ceyebrows\u201d sign on (18) F FDG PET\/CT","volume":"21","author":"Vankadari","year":"2022","journal-title":"World J Nucl Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1843169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:11:47Z","timestamp":1779376307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1843169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1843169"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1843169","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1843169"}}